MFN2 Cancer Research Results

MFN2, Mitofusin 2: Click to Expand ⟱
Source:
Type:

MFN1, MFN2, and OPA1 are mostly AD / neurodegeneration-relevant pathway targets: In AD, the general pattern is: fusion proteins MFN1, MFN2, and OPA1 tend to be reduced or functionally impaired, while fission signaling such as DRP1/FIS1 is often increased, contributing to fragmented mitochondria, synaptic injury, oxidative stress, and impaired bioenergetics

MFN1, MFN2, and OPA1 are mitochondrial fusion regulators. MFN1 and MFN2 mediate outer mitochondrial membrane fusion, while OPA1 mediates inner mitochondrial membrane fusion and helps maintain cristae structure. In Alzheimer’s disease and related neurodegenerative models, mitochondrial dynamics are commonly shifted toward excessive fragmentation, with reduced or impaired fusion signaling and increased fission stress. Restoring MFN2/OPA1/MFN1 activity may help preserve mitochondrial network integrity, oxidative phosphorylation, neuronal transport, calcium handling, and synaptic resilience.

Target / Pathway Primary Disease Relevance Normal Function Observed / Suspected Change in AD Therapeutic Direction Database Interpretation Evidence Strength Notes for Product Screening
MFN1 Mostly AD / neurodegeneration; secondary cancer relevance Outer mitochondrial membrane fusion protein. Works with MFN2 to tether and fuse adjacent mitochondria, helping maintain mitochondrial network integrity and mitochondrial DNA/protein complementation. Generally reported as reduced or functionally impaired in AD-related mitochondrial dynamics imbalance, contributing to mitochondrial fragmentation and reduced neuronal bioenergetic resilience. Support / restore mitochondrial fusion where excessive fission and mitochondrial fragmentation are present. Pathway target rather than product. Useful as part of a broader “mitochondrial fusion support” or “anti-fragmentation” pathway entry. Moderate Track products that increase MFN1 expression, improve mitochondrial network morphology, reduce DRP1-driven fragmentation, or restore fusion/fission balance.
MFN2 Strong AD / neurodegeneration relevance; also cancer and metabolic relevance Outer mitochondrial membrane fusion protein. Also involved in mitochondria-ER contact regulation, calcium handling, mitophagy-related quality control, mitochondrial trafficking, and cellular stress adaptation. MFN2 dysfunction or downregulation is associated with impaired mitochondrial fusion, abnormal mitochondria-ER communication, calcium stress, oxidative stress, synaptic vulnerability, and possibly amyloid/tau-associated mitochondrial injury. Usually upmodulation / restoration is desirable in AD models where mitochondrial fragmentation, poor transport, or excessive fission is present. High-priority AD target. Best entered as a mitochondrial dynamics, fusion, ER-mitochondria contact, and mitophagy-quality-control target. Moderate-Strong Track products that increase MFN2, improve mitochondrial elongation, reduce Aβ/tau-induced mitochondrial fragmentation, improve calcium homeostasis, or restore mitochondrial transport in neurons.
OPA1 Strong AD / neurodegeneration relevance; also apoptosis and cancer relevance Inner mitochondrial membrane fusion protein. Maintains cristae structure, supports oxidative phosphorylation, preserves mitochondrial membrane organization, and helps regulate cytochrome-c release during apoptosis. OPA1 loss or cleavage can reduce inner membrane fusion, destabilize cristae, impair oxidative phosphorylation, increase mitochondrial fragmentation, and sensitize neurons to synaptic and metabolic stress. Support / stabilize OPA1 activity, especially long-form fusion-active OPA1, where mitochondrial stress causes excessive OPA1 cleavage and fragmentation. High-priority AD target. Best entered under mitochondrial fusion, cristae integrity, oxidative phosphorylation, and apoptosis-resistance pathways. Moderate-Strong Track products that preserve OPA1, reduce pathological OPA1 cleavage, improve cristae integrity, improve ATP production, or reduce mitochondrial apoptosis signaling.


Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
6461- 1,8-Cin,    1,8-cineole (eucalyptol): A versatile phytochemical with therapeutic applications across multiple diseases
- Review, AD, NA - Review, Var, NA
*Inflam↓, *antiOx↑, *neuroP↑, *BioAv↑, *Half-Life↝, *toxicity↓, *PGE2↓, *TNF-α↓, *IL1β↓, *NO↓, *NF-kB↓, *PPARγ↓, COX2↓, *ROS↓, *SOD↑, *Catalase↑, *TAC↑, *MDA↓, *lipid-P↓, *NRF2↑, *HO-1↑, *NADPH↑, *GPx↑, *AntiBio↑, *eff↑, *AntiFungal↑, *AntiViral↑, *TRPA1↑, eff↑, TumCCA↑, ROS↑, MAPK↝, mTOR↝, Apoptosis↑, survivin↓, Akt↓, p38↑, cl‑PARP↑, cl‑Casp3⇅, P53↑, BAX↑, Cyt‑c↑, Casp9↑, Dose↝, *Aβ↓, *tau↓, *GSK‐3β↓, *BACE↓, *cardioP↑, MFN2↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned

MFN2↑, 1,  

Redox & Oxidative Stress

ROS↑, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   cl‑Casp3⇅, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   MAPK↝, 1,   p38↑, 1,   survivin↓, 1,  

DNA Damage & Repair

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

mTOR↝, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,  

Drug Metabolism & Resistance

Dose↝, 1,   eff↑, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


NA, unassigned

AntiBio↑, 1,   TRPA1↑, 1,  

Redox & Oxidative Stress

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,   TAC↑, 1,  

Core Metabolism/Glycolysis

NADPH↑, 1,   PPARγ↓, 1,  

Proliferation, Differentiation & Cell State

GSK‐3β↓, 1,  

Angiogenesis & Vasculature

NO↓, 1,  

Immune & Inflammatory Signaling

IL1β↓, 1,   Inflam↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission

tau↓, 1,  

Protein Aggregation

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance

BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Functional Outcomes

cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome

AntiFungal↑, 1,   AntiViral↑, 1,  
Total Targets: 32

Scientific Paper Hit Count for: MFN2, Mitofusin 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:1490  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page